Summary of the effect of ibandronate on mean lumbar spine BMD, relative to baseline, after 12 months of treatment (%)
| Stratum | Placebo | Ibandronate | |||
|---|---|---|---|---|---|
| T score | Time since menopause (years) | 0.5 mg | 1.0 mg | 2.0 mg | |
| *Difference between active group and placebo was significant (p<0.05), even when a Bonferroni correction was applied; †According to an ANOVA test, the difference between active group and placebo was significant (p<0.05). Significance was not achieved when a Bonferroni correction was applied. | |||||
| >−1 | 1–3 | −0.0 | 1.1 | 1.1 | 1.8† |
| ⩽−1, ⩾ −2.5 | 1–3 | −0.7 | 0.4 | 1.9* | 2.8* |
| >−1 | >3 | −0.4 | 1.4† | 1.9* | 1.9* |
| ⩽−1, ⩾ −2.5 | >3 | −0.2 | 1.4* | 2.2* | 2.9* |